Proton therapy safer than older radiotherapies for esophageal cancer
the ONA take:
According to new researcher presented at the annual conference of the Particle Therapy Cooperative Group in San Diego, California, researchers from the University of Maryland School of Medicine in Baltimore have found that patients with esophageal cancer treated with proton therapy experienced significantly fewer adverse events than patients treated with conventional radiation therapies.
For the study, researchers identified about 600 patients with esophageal cancer and found that proton therapy was associated with significantly fewer incidents of nausea, blood abnormalities, and loss of appetite than older radiation therapies.
Proton therapy has shown efficacy in various types of cancer, including brain, breast, esophageal, head and neck, liver, lung, prostate, and spinal cord cancers. It is expected that up to 30% of patients with cancer will benefit from targeted proton beam therapy, which can precisely target tumors while reducing radiation to healthy issue.
"This evidence underscores the precision of proton therapy, and how it can really make a difference in cancer patients' lives," said Michael Chuong, MD, an assistant professor of radiation oncology at the University of Maryland School of Medicine.
Patients with esophageal cancer treated with proton therapy experienced significantly fewer adverse events.
- Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma
- Acupuncture May Improve Fatigue in Patients with Lung Cancer
- "Light" Cigarettes and Cancer Risk (Fact Sheet)
- A Review of CDK4/6 Toxicities and Interactions Management in Breast Cancer
- Vitamin D3 Supplementation Has No Impact on Breast Density Percentage, Breast Cancer Risk
- Dexamethasone-Induced Hiccups in Chemotherapy May be Prevented by Rotating to Methylprednisolone
- New Evidence Shows Metastases May Spread Independently of Lymph Nodes
- Long Term Survivors of Prostate Cancer Express Treatment Decision Regret for Up to 15 Years
- FDA Expands Clearance for Cooling Cap Use With Chemotherapy for Solid Tumors
- Recommendations for Vaccine Administration During Chemotherapy
- Risk for Prostate Cancer Not Associated With Vasectomy, Meta-analysis Affirms
- Disease-Free Survival After Breast Cancer Comparable With Exemestane, Sequential Tamoxifen/Exemestane
- Treating the Other "Patient": Depressive Symptoms Are Predictive of Declining Physical Health in Caregivers
- Oropharyngeal Mucositis Pain Effectively Relieved With Indomethacin Oral Spray
- Opioids Overprescribed in Patients Undergoing Surgery
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|